Navigation
banner

Diabetes Summit

2018-01-222018-02-272018-01-19
EARLY BIRD DISCOUNT! Register by Feb 27, 2018 to receive 10% off your registration!
Or Register 3 for the price of 2 with the coupon code rcdvb!


PLENARY KEYNOTE SPEAKERS
Domenico Accili

Domenico Accili
Professor of Medicine
Columbia University
Domenico Accili
Professor of Medicine
Columbia University
 
About Speaker:
Nir Barzilai

Nir Barzilai
Professor, Department of Medicine (Endocrinology); Professor, Department of Genetics
Albert Einstein College of Medicine
Nir Barzilai
Professor, Department of Medicine (Endocrinology); Professor, Department of Genetics
Albert Einstein College of Medicine
 
About Speaker:
Andrew Young

Andrew Young
Vice President, Chief Scientific Officer
Intarcia
Andrew Young
Vice President, Chief Scientific Officer
Intarcia
 
About Speaker:
PLENARY SPEAKERS
Brian Bloomquist

Brian Bloomquist
Senior Director, Global External Research and Development
Eli Lilly
Brian Bloomquist
Senior Director, Global External Research and Development
Eli Lilly
 
About Speaker:

Brian has been at Eli Lilly since April 2006 where his role within the Diabetes External Innovation group is to lead the evaluation of external partnering opportunities in diabetes and endocrine disease for technical merit and portfolio fit.  Prior to coming to Lilly, he spent 11 years in the Metabolic Disorders group at Bayer Pharmaceuticals where his laboratory was engaged in obesity drug discovery and he held multiple leadership positions in the management of the Obesity Research portfolio.  Brian completed his post-doctoral studies at The Johns Hopkins University School of Medicine where he studied dopaminergic signaling in the laboratory of Dr. Betty Eipper following his graduate studies at Purdue University where he investigated Drosophila photoreceptor signal transduction under Dr. William Pak and his thesis was awarded the first A.H. Ismail Interdisciplinary Dissertation Award.  Dr. Bloomquist has been a speaker or panelist at multiple conferences including Bio-Europe, GTC Bio, Mass Bio, Ausbiotech, and the Queensland Investment Forum, has been cited in Close Concerns, a leading diabetes and obesity healthcare information company, is an inventor on a number of patents, and is the author of multiple peer-reviewed publications, including an article highlighted on the cover of the journal Cell. 

Alan Cherrington

Alan Cherrington
Professor of Molecular Physiology and Biophysics
Vanderbilt University
Alan Cherrington
Professor of Molecular Physiology and Biophysics
Vanderbilt University
 
About Speaker:

Over the past 44 years Dr. Cherrington has carried out important metabolic research using the conscious dog as a model. During that period he, his colleagues and trainees developed an array of unique surgical approaches (trans-hepatic, renal, gut, head, limb cannulation, 3rd ventricle cannulation, liver and renal denervation, carotid body resection, adrenalectomy, pancreatectomy and duodenal bypass) which when combined with clamping (hormone, metabolite) techniques have allowed the performance of experiments not possible anywhere else in the world. Using the dog, which has high translation value to the human, the Cherrington lab can measure whole body metabolism at the same time as organ balance and molecular signaling (using biopsies). In addition they developed a model of T1DM using alloxan, as well as a model of T2DM using diet manipulation. Using this array of techniques and models the Cherrington lab has assessed the way in which hormones, neural mediators, and metabolites interact to control hepatic glucose production (glycogenolysis/gluconeogenesis) and liver glucose uptake (and storage) in the conscious dog. Their work has resulted in almost 300 peer reviewed papers, as well as 87 review articles. It has been recognized with numerous honors including the Lilly and the Banting Awards for research from the ADA and the Rumbough Award for research from the JDRF.

About twelve years ago Dr. Cherrington decided to devote a significant portion of his research effort to helping expedite drug discovery and device development within the pharmaceutical sector. He set up a structure that provided four opportunities for interaction with pharma and bio-tech partners, 1) consulting, 2) direct help with experiments at a given pharma site, 3) contract research within Vanderbilt and lastly 4) contract research with a 3rd party CRO. This menu of services was based on his many years of experience in the field, as well as the ability to carry out unique proof of concept studies utilizing his conscious dog models. He has now worked with a majority of the major pharmaceutical companies (Merck, Novo Nordisk, Eli Lilly, Sanofi, GlaxoSmithKline, Bristol Myers Squib, Hoffman LaRoche, Biocon, Pfizer, Gilead, Boehringer Ingelheim, Boston Scientific, Abbott, Amylin, Takeda, Tanabe) and many small bio-techs (Abvance, Calibr, Fractyl, Galvani, Metavention, NuSirt, Sensulin, Metabasis, Inhale Therapeutics, Silver Lake, Thermalin, Thetis, VTv Therapeutics, Viacyte, Viking, Zafgen, NGM, OSI). The work performed in Cherrington’s lab was often important in shaping the direction of internal programs and in establishing the credibility of a particular approach both within and without the company. Many of the study outcomes have now been published in peer reviewed journals. Of particular note is the work carried out to investigate novel insulin analogues (Biocon – oral insulin; Novo Nordisk – hepatic-preferential insulin; Eli Lilly – hepatopreferential insulin; Thermalin – ultra rapid insulin; Pfizer – inhaled insulin; Merck – glucose responsive insulin). Likewise, work with GLP-1 (Amylin), incretin mimetics (Amylin) and DPPIV (BMS) inhibitors helped advance that class of compounds. More recently the lab has been working in the electroceutical field (Boston Scientific, Galvani, and Metavention) to establish the feasibility of using nerve stimulation or blockade to alter metabolic regulation in vivo. Finally, it should be noted that Dr. Cherrington’s lab has also carried out studies focused on SGLT-2 inhibitors, 11betaHSD 1 blockers, glucagon receptor antagonists, as well as glucokinase activators. It is worth noting that his collaborations are international, such that he has worked with companies around the world including those based in the USA, Germany, France, Denmark, Japan, Switzerland and India. By offering his expertise and unique models to others he has provided important input into decision making within the pharmaceutical and bio-tech world.

Alexander (Zan) Fleming

Alexander (Zan) Fleming
President & Chief Exective Officer
Kinexum
Alexander (Zan) Fleming
President & Chief Exective Officer
Kinexum
 
About Speaker:

Dr. Alexander Fleming received his M.D. and internal medicine training from Emory, fellowship training in endocrinology at Vanderbilt and metabolism at National Institutes of Health, where he was a senior fellow. From 1986-98 Dr. Fleming served as reviewer and supervisory medical officer at the US Food and Drug Administration.  He acquired extensive clinical experience and regulatory responsibility in the therapeutic areas of diabetes, other metabolic and endocrine disorders, growth and development, nutrition, lipid-lowering compounds, orphan drug indications, and reproductive indications.  He led reviews of landmark approvals including those of the first statin, insulin analog, metformin, PPAR-agonist, and growth hormone for non-GH deficiency indications. He was responsible for the regulation of the earliest biotech products including human insulin and growth hormone.  He helped to shape a number of FDA policies and practices related to therapeutic review and regulatory communication.

His regulatory and technical expertise has been requested in numerous international settings including the World Health Organization, where he was assigned during 1991-92.  Dr. Fleming was a member of the expert working groups on Good Clinical Practices and General Considerations for Clinical Trials of the International Conference on Harmonization (ICH) and participated on other ICH committees including the Common Technical Document working group. 

He was also the founder and editor in chief of the Virtual Journal of Drug Evaluation, of FDA's Center for Drug Evaluation and Research (CDER), a major contributor to FDA's Good Review Practice (GRP) initiative, and chair of the committee responsible for education and training at CDER.   He conceived and led the first FDA pilot project to utilize the internet for regulatory communication. Dr. Fleming is lead author of the book, “Optimizing Development of Therapies for Diabetes.” He has frequently published scientific articles and book chapters, the most recent chapter, Regulatory Considerations for Early Clinical Development, is in Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development, published by Springer in January 2015.  He has been a member of number corporate and professional society advisory boards.  The most recent is the joint European Association for the Study of Diabetes and American Diabetes Association working group on insulin pump safety. 

Dr. Fleming founded Kinexum, a strategic advisory firm in 2003 and continues to serve as its chief executive officer.

Diabetes Partnering & Deal-Making
DISTINGUISHED SPEAKERS
Alan Carter

Alan Carter
PharmD, Product Development/Repository Management
MRIGlobal/UMKC School of Pharmacy
Alan Carter
PharmD, Product Development/Repository Management
MRIGlobal/UMKC School of Pharmacy
 
About Speaker:

Principal Investigator, Senior Advisor for Pharmaceutical Sciences, and Pharmacist Manager, May 2012-present MRIGlobal, Kansas City, Missouri Serves as Principal Investigator for the NIH-NCATS Drug Substance Development and Manufacture (DSDM) and NINDS Drug Manufacturing and Formulation Program (DMFP). Ensures production is optimized under cGLP and cGMP conditions, formulation development, packaging of API according to clinical trial protocol, and data is provided by MRIGlobal appropriately for submission to the FDA to support IND filings for new drug entities. Advises MRIGlobal government and commercial clients on API production and formulation, drug metabolism and kinetics, potential biomarker targets, and large molecule comparison analysis. Supports the NIH-NCI Division of Cancer Prevention (DCP) Centralized Chemopreventive Agent Repository (CCAR) and the Shelf-Life Stability Program for the NCI Developmental Therapeutics Branch (DTP) as a subject matter expert. Provides investigational agent development guidance and clinical trial support for commercial clients. Manages all pharmacy operations and maintains clinical trial subject record retention/retrieval capabilities, as necessary, to distribute investigational medications to study sites in a blinded fashion. Provides reports to NCATS, NINDS, NCI, and commercial clients in the manner and format requested. Maintains sufficient staffing and ensures proper training to meet contractual and licensing requirements. Other duties as required to provide research pharmacy services and education programs. Adjunct Clinical Assistant Professor of Pharmacy Practice, 1993-present UMKC School of Pharmacy, Kansas City, Missouri Provides lectures, continuing education programs, student evaluations, and testing as both scheduled and guest Assistant Professor. Precepts Pharm. D. candidates, assists in student health fairs, and conducts other student/practitioner activities.

• Serves on University of Missouri Research Board as Subject Matter Expert

• Provides grant application review

• Investigational product and device use evaluation trials and publications

• Provides peer review and subject matter expert review

Joseph Cook

Joseph Cook
President and Executive Chairman of the Board
Nusirt Inc.
Joseph Cook
President and Executive Chairman of the Board
Nusirt Inc.
 
About Speaker:
Scott Johnson

Scott Johnson
Communications Lead
mySugr GmbH
Scott Johnson
Communications Lead
mySugr GmbH
 
About Speaker:

Scott is an experienced patient advocate. He works with a wide range of stakeholders across the healthcare environment to help them establish effective communication with the patient community. His expertise in the diabetes social media space is recognized worldwide and he advises organizations within the healthcare, food, and consumer goods industries.

Today he is Communications Lead, USA for mySugr and Patient Pathways Lead in the Diabetes Division of Delta Project Management. He manages a long-standing and award-winning blog “Scott's Diabetes” that reaches hundreds of thousands of people annually.

Scott is also a member of the Children with Diabetes faculty where he develops educational curriculums and content for the Friends for Life annual conference and regional events. He is on the Executive Committee of the Board of Directors for the Diabetes Hands Foundation, the Board of Directors for the Diabetes Community Advocacy Foundation, and is a founding member of Partnering for Diabetes Change, a coalition of people living with diabetes and industry representatives working to support underserved communities. He is interested in how these types of interactions including peer-to-peer support impact patient outcomes and routinely presents his work.

Aaron Schwartz

Aaron Schwartz
Director, R&D Innovation Sourcing
Novo Nordisk Inc.
Aaron Schwartz
Director, R&D Innovation Sourcing
Novo Nordisk Inc.
 
About Speaker:

Aaron is a Director in Novo Nordisk’s R&D Innovation Sourcing team.  In this capacity, Aaron is responsible for the search an evaluation of new therapeutics and enabling technologies for protein, peptide, and antibody drugs.  Prior to joining Novo Nordisk, Aaron worked in the MIT Technology Licensing Office for 13.5 years.  During this time, he worked on license and sponsored research agreements with life sciences companies from startups to big biotech/pharma and everything in between.  He also managed a portfolio of over 650 technologies.  Before Aaron’s time at MIT, he was a management consultant to big pharma and a startup.  Aaron has an undergrad degree in biology from the University of Chicago and a Masters degree in biology from MIT.

Diabetes Drug Discovery & Development
DISTINGUISHED SPEAKERS
William W. Bachovchin

William Bachovchin
Professor, Department of Biochemistry
Tufts University School of Medicine
William Bachovchin
Professor, Department of Biochemistry
Tufts University School of Medicine
 
About Speaker:

Dr. Bachovchin serves as Executive Vice President and Chief Scientist and member of the board of directors of Arisaph pharmaceuticals since he co-founded the company in 1999. He was also a co-founder of Point Therapeutics which was a publically traded biotechnology company prior to its merger with Dara BioSciences. Dr. Bachovchin is also Professor of Biochemistry at Tufts University School of Medicine.

Dr Bachovchin received a BS degree in Biology from Wake Forest University a doctoral degree in Chemistry from The California Institute of Technology, and did postdoctoral work at Harvard Medical School before arriving at Tufts. Dr. Bachovchin is an author on more than 100 peer reviewed journal articles, and an inventor on more than 30 issued patents as well as numerous pending applications. Dr. Bachovchin is a leader in the areas of NMR spectroscopy, enzymes mechanisms and drug design and discovery, especially in areas pertaining to the post proline cleaving family of enzymes. To date three drugs designed by Dr. Bachovchin have entered human clinical trials and several more are in late stage preclinical testing.

Jonathan Behr

Jonathan Behr
Managing Director
JDFR
Jonathan Behr
Managing Director
JDFR
 
About Speaker:

Jon joined the T1D Fund from Partners Healthcare Innovation, where he was a Market Sector Leader and Executive in Residence, driving technology translation from research hospitals affiliated with Harvard Medical School. He previously held senior venture creation roles including Vice President of New Ventures for Enlight Biosciences and Principal at PureTech Ventures (LON:PRTC). Jon has co-founded and supported seven companies (including holding C-level operating, business development and board director positions) and managed alliances with top pharmaceutical companies. He earned his Ph.D. at Massachusetts Institute of Technology as a Howard Hughes fellow and his B.S. from Rice University.

Denise Faustman

Denise Faustman
Director of Immunobiology; Associate Professor of Medicine
Massachusetts General Hospital; Harvard Medical School
Denise Faustman
Director of Immunobiology; Associate Professor of Medicine
Massachusetts General Hospital; Harvard Medical School
 
About Speaker:

Denise Faustman, MD, PhD, is Director of the Immunobiology Laboratory at the Massachusetts General Hospital (MGH) and an Associate Professor of Medicine at Harvard Medical School. She is currently leading a clinical trial program investigating the potential of the BCG vaccine as a disease reversal treatment for long-standing type 1 diabetes. Her research accomplishments include the first scientific description of modifying donor tissue antigens to change their foreignness, the identification of interrupted T cell education through MHC class I, and the identification of autoimmune T cell sensitivity to TNF. For both autoreactive CD8 T cells she has identified the TNFR2 receptor as central and also the TNFR2 receptor for the expansion of beneficial Treg cells.  These achievements have earned her awards including the National Institutes of Health and National Library of Medicine “Changing the Face of Medicine” Award as one of 300 American physicians (one of 35 in research) honored for seminal scientific achievements in the United States, the Oprah Achievement Award for “Top Health Breakthrough by a Female Scientist,” and the Women in Science Award from the American Medical Women’s Association and Wyeth Pharmaceutical Company.  Dr. Faustman’s research has been highlighted in publications including Science, Nature, The Wall Street Journal, The New York Times, Los Angeles Times, The London Financial Times and Scientific American. She earned her MD and PhD from Washington University School of Medicine, in St. Louis, Missouri, and completed her internship, residency, and fellowships in Internal Medicine and Endocrinology at the Massachusetts General Hospital.

 

Robert Geho

Robert Geho
Co-Founder and Chief Executive Officer
Diasome Pharmaceuticals Inc
Robert Geho
Co-Founder and Chief Executive Officer
Diasome Pharmaceuticals Inc
 
About Speaker:

Robert Geho is co-founder and CEO of Diasome Pharmaceuticals, Inc., a privately-held developer of liver targeting systems for insulin and other drugs to treat diabetes.  Working alongside a team of nanotechnology formulation and protein chemistry experts, highly experienced clinical research professionals, and globally recognized investors, Robert is actively involved in the clinical development of Diasome’s Hepatocyte Directed Vesicle “HDV”) system.  HDV Insulin is Phase 3-enabled and is currently being tested in a multi-center Phase 2b study in patients with Type 1 diabetes.

David Maggs

David Maggs
Chief Medical Officer
Fractyl Laboratories
David Maggs
Chief Medical Officer
Fractyl Laboratories
 
About Speaker:
Felicia Pagliuca

Felicia Pagliuca
Vice President, Cell Biology R&D
Semma Therapeutics
Felicia Pagliuca
Vice President, Cell Biology R&D
Semma Therapeutics
 
About Speaker:

Dr. Pagliuca currently serves as Vice President of Cell Biology Research and Development and is scientific co-founder of Semma Therapeutics. She leads cell-based research and development and plays a key role in supporting Semma's preclinical, regulatory, and manufacturing strategies for its cell therapy products. Felicia also works closely with Semma’s senior leadership on corporate development activities, including key collaborations and partnerships. Previously, Felicia was a postdoctoral fellow in Professor Doug Melton’s laboratory at the Harvard Stem Cell Institute. Felicia was part of the team in the Melton lab that discovered how to generate stem cell derived beta cells and published a seminal paper in Cell in 2014. She is an expert in stem cell biology and diabetes and one of the inventors of Semma Therapeutics’ key technologies. Felicia received a B.S. from Duke University and a Ph.D. from Cambridge University where she was a Marshall Scholar. She is currently on leave from Harvard Business School where she was a Kaplan Fellow.

Michael Zemel

Michael Zemel
Founder and Chief Scientific Officer
Nusirt Inc.
Michael Zemel
Founder and Chief Scientific Officer
Nusirt Inc.
 
About Speaker: